A Sequence of Alzheimer’s Disease
This article is brought to you by the kind folks at Aarkstore Enterprises. You can visit their website for the most comprehensive Market Research
Alzheimer has been long associated with people who are detected with dementia. Although both vary in the nature of onset and effect to a different population, they are mostly seen with persons who are an advent towards the older stage. Consequently, Alzheimer is a progressive form of Dementia. The broader term for a variety of conditions that are caused due to injuries and diseases that negatively affect the capacity to think and cooperate. Ordinarily, the changes affect and interfere in day to day living cycles of individuals.
Signs and Symptoms
People affected with Alzheimer have issues in performing tasks like brushing, washing hair or even tasks that require steps like finding a house in the busy street. There is often a lack of motivation and social isolation. They often tend to wonder at places such as a busy street or shopping mall.
Alzheimer patients often behave outrageously angry. Aggression is a common symptom which leads to stress build up to close ones. Hand-wringing, Pacing and Rocking or even at times lustfulness are common responses. Additionally, sleep problems and hallucinations often cause them to imagine things which cannot have existence.
Dealing with the patient
Communication is the key to deal with patients of Alzeimers, often they tend to fake their illness and try to act normal. It is needed that they should be dealt with patience and care as a simple misunderstanding can create emotional stress in the patients.
How is the Disease growing?
The Alzheimer’s Association reports cases of people affected in Alzheimer’s condition to an overall 60 to 80 per cent of dementia cases. The reporting was carried out in the age group of 25-80 years of population. The study found the cases were mostly observed in the age group of over 65 years. Diagnosis greatly varies and if done just before the age group affected, then it can be checked. Early onsets of the disease start at an age group of 55-60 years.
As far as treatments are done, little is known about them. They have been subjected to a lot of contradictions. These treatments are only applicable to slow down the onset of the progression.
There’s no cure for Alzheimer, but there are methods that can decrease the progress of the disease. A large population still finds difficult to generalize Alzheimer and know the symptoms, various websites provide distinct views of facts about the condition of Alzheimer disease.
Current overview of research.
The increasing growth in Alzheimer condition has made a start in Alzheimer’s disease in the therapeutics market worldwide. Market research reports analyze the current value to be at 47 Million on an overall scale in the projected score of people suffering from the disease. The number is further estimated to reach 50 Million by the end of 2020, as reports suggest there has been an increasing number of patients in Alziemer every day.
The common factors include age in most of the general population. Consequently, this provides a growth to rising opportunities in the Alzheimer’s treatment market. United Nations estimates as much as 962 million people being in the age group of above 60 years who are at risk of Alzheimer. Subsequently, this is accounted for 13 per cent of the global population, with the number being subjected to reach 1.4 billion in 2030. This values for an annual rate of 3 per cent per year.
Countries like Europe has been listed for the vast population affected by Alzheimer followed by the Asia Pacific which accounts to 900 Million by 2025. India is on the lesser side with considerably 1 million cases annually. The disease therapeutics market is led by North America which estimates 6 million patients in the coming decade. The reason is the health care system and technologies on the rise, giving the market for Alzheimer a push.
People experiencing from the first stage of Alzheimer’s disease, along with Dementia do not have appropriate access to healthcare infrastructure for treating the disease. World Alzheimer report suggested that only 50 per cent of patients who suffer from the disease are undergoing diagnosis. This rate of diagnosis is further lessened to 10 per cent in low and middle-class income economies. This will lead to the growth of Alzheimer drugs market. The current statistics say there has been no diagnosis for the disease.
Currently, only biomarker tests are involved with knowing the amount of beta-amyloid present in the brain. This visualizes the positron emission tomography imaging and is still in the research diagnosis to develop a definitive treatment. The drugs for Alzheimer’s therapy are in the pipeline system and are expected to launch in the coming decade. It is a propelling growth of Alzheimer’s disease therapeutics market.